Current Report · Items 7.01, 9.01 · 8-K

Ligand Pharmaceuticals Incorporated

LGNDNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Sep 22, 2026Accepted Sep 22, 2026, 7:08 AM EDTCIK 886163Accession 0000886163-26-000050

Company context

Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Current securities

LGNDNASDAQ · EQUITY · Current LGNDZOTC · RIGHT · Current LGNXZOTC · RIGHT · Current LGNYZOTC · RIGHT · Current LGNZZOTC · RIGHT · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 22, 2026, Ligand Pharmaceuticals Incorporated (“Ligand”) issued a press release announcing that it had acquired royalty and milestone payment rights relating to Santen Pharmaceutical Co., Ltd.’s Ryjunea® from Sydnexis, Inc. for $23 million upfront (the “Transaction”), and certain other information regarding the Transaction. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.